Mangoceuticals announced a strategic partnership with Eli Lilly and Novo Nordisk that will launch two new programs—MangoRx Direct and PeachesRx Direct—on its telehealth platform. The collaboration gives the company exclusive rights to sell the GLP‑1 weight‑loss drugs Zepbound and Wegovy, with fulfillment handled by Lilly’s LillyDirect Self‑Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy.
The deal is designed to diversify Mangoceuticals’ revenue base, which has been heavily concentrated in men’s wellness products such as erectile dysfunction and hair‑loss treatments. By adding high‑margin weight‑loss drugs, the company can tap a rapidly expanding market and reduce its reliance on legacy product lines. The partnership also introduces a new pricing model: a $99‑per‑month medication‑management membership and a cash‑pay price for GLP‑1 drugs starting at $499 per month, which aligns with the company’s goal of making weight‑loss treatment affordable and sustainable.
Mangoceuticals has faced a steep decline in revenue and significant net losses in recent quarters, with liquidity concerns highlighted in its latest filings. The partnership is therefore seen as a potential turnaround catalyst, offering a new revenue stream that could offset the company’s historical financial headwinds. Management has emphasized that the high‑margin drugs will help improve cash flow and support ongoing investments in its telehealth infrastructure.
The announcement triggered a sharp market reaction, with the stock surging in pre‑market trading and rising 24.43% in early trading on the day of the announcement. Investors reacted strongly to the prospect of entering the lucrative GLP‑1 market, which is expected to generate substantial incremental revenue and improve profitability.
CEO Jacob Cohen stated, “We’re working to make world‑class weight‑loss treatment simple and sustainable.” He added that the partnership will enable Mangoceuticals to deliver proven therapies to a broader patient base while maintaining its focus on affordability and patient support. The company’s leadership views the deal as a key step toward stabilizing its financial position and positioning it for long‑term growth in the obesity‑treatment market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.